A Phase 2 Study to Evaluate the Efficacy and Safety of BPN14770 in Participants with Mild Alzheimer's Disease

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, and Open-label, Single-arm, Extension Study to Evaluate the Efficacy and Safety of BPN14770 in Participants with Mild Alzheimer's Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210149

Enrollment

200

Registered

2021-06-14

Start date

2021-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild Alzheimers disease

Interventions

oral administration of BPN14770 or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants who meet the criteria for probable AD dementia according to the Alzheimer's disease diagnostic criteria by National Institute on Aging-Alzheimer's Association (NIA-AA) and also meet the following criteria resulting in a clinical diagnosis of mild Alzheimer's disease. 1. CDR global score of 0.5 or 1 with a memory score of >= 0.5 at screening and prior to administration of study intervention. 2. MMSE score of 20 to 26 at screening.

Exclusion criteria

Exclusion criteria: Any medical or neurological condition (other than mild Alzheimer's disease) that might have been a contributing cause to the participant's cognitive impairment, including Lewy body dementia and frontotemporal dementia.

Design outcomes

Primary

Measure	Time frame
Change from baseline in ADAS-Cog 13 score at Week 24	—

Contacts

Public Contact- Corporate Communications Department

Shionogi & Co., Ltd.

shionogiclintrials-admin@shionogi.co.jp+81-6-6209-7885

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026